InvestorsHub Logo
Followers 800
Posts 50877
Boards Moderated 2
Alias Born 12/12/2004

Re: Invest-in-America post# 15

Tuesday, 08/09/2022 8:41:30 PM

Tuesday, August 09, 2022 8:41:30 PM

Post# of 69
.65 in AH > oversold! > Mizuho Securities Sticks to Its Buy Rating for eFFECTOR Therapeutics (EFTR)
August 09 2022 - 08:25PM
TipRanks

Share On Facebook
In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on eFFECTOR Therapeutics (EFTR - Research Report), with a price target of $20.00. The company's shares closed yesterday at $0.65.According to TipRanks, Goldstein is a 3-star analyst with an average return of 2.4% and a 36.62% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, IN8bio, and Incyte.Currently, the analyst consensus on eFFECTOR Therapeutics is a Strong Buy with an average price target of $26.00.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $40.42 and a one-year low of $0.75.
https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-its-buy-rating-for-effector-therapeutics-eftr-2?utm_source=advfn.com&utm_medium=referral

New York Yankees and Duke Basketball

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EFTR News